Financial Daily from THE HINDU group of publications
Friday, Sep 30, 2005


News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate - Announcements


Dr Reddy's in deal with Danish co for diabetes drug

Our Bureau

Hyderabad , Sept. 29

A DAY after floating the country's first integrated drug development company, Dr Reddy's Laboratories has entered into a co-development and commercialisation agreement with the Denmark-based Rheoscience A/S for joint development and commercialisation of Balaglitazone (DRF-2593), a molecule for the treatment of type-2 diabetes.

Under the terms of the agreement, Rheoscience will fund all costs associated with the phase-III clinical trials of DRF-2593 and Dr Reddy's will pay Rheoscience a pre-determined amount towards its share of the development costs.

Rheoscience will retain marketing rights in the European Union and China, while Dr Reddy's will have the rights for the US and rest of the world. Rheoscience needs to obtain all necessary regulatory approvals on behalf of Dr Reddy's in the US. On receiving final approval from the USFDA, Dr Reddy's will make a pre-determined milestone payment to Rheoscience.

In a press release here on Thursday, Dr Reddy's said the agreement would be valid for 10 years from the date of commercialisation. However, the company did not disclose the financial terms and conditions.

Under the agreement, if the partners choose to commercialise the product on their own, then the partners have to pay each other a staggered royalty on the sales. However, if the partners choose to commercialise the product through a third party, then each partner is entitled to share a pre-determined percentage of the net proceeds of commercialisation received by it with the other partner. Dr Reddy's said it will also retain the right to supply clinical development and commercial quantities on arms-length basis.

Commenting on the co-development deal, Dr Reddy's Chief Executive Officer, Mr G.V. Prasad, said, "This deal provides Dr Reddy's with an opportunity to commercialise new commercial entities (NCEs) in key markets, thereby transforming Dr Reddy's into an innovation-driven business."

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Share Infoline Tata Safari Dicor

Stories in this Section
Yamaha spins off new sales, marketing subsidiary


Eveready sells Chennai property for Rs 72 cr
Color Chips bags $2.5 million BKN order
Dr Reddy's in deal with Danish co for diabetes drug
OVL bags offshore block in Vietnam
J.B. Chem drug gets US nod
Natco allots shares to Jermyn
The ONGC stand-off — Should PSUs remain govt departments or behave like corporates?
Escorts may exit from more jt ventures
Fortis hopes to partner Naresh Trehan in Medicity project
Havell's India to merge Crabtree with itself
TCS sets up 4th corporate research lab in Delhi
Samkrg plans expansion
Ansaldo group co in tie-up with G.B. Engg for power plants
NTPC firms up oil exploration foray
NTPC's hydro initiative gathers steam — Projects totalling 4,400 MW on the anvil
Alfa Laval eyes India, China to source material
SPIC hopeful of revision in urea pricing mechanism
BHEL net up 45 pc, to pay 80 pc
Dredging Corpn declares 120 pc dividend
PTC reappoints T.N. Thakur as CMD
Chairman of Baldota Group passes away


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line